![7-26-21_GenDen 7-26-21_GenDen](/images/default-source/publication-images/this-week-at-agd/7-26-21_genden.tmb-medium.jpg?sfvrsn=afe9fd34_1)
Though pilocarpine is indicated for the treatment of xerostomia, the systemic use of this drug may promote adverse reactions — exacerbated sweating, increased urinary frequency, tiredness, headache, dizziness, nausea — that make it unviable. Topical, controlled-release formulations of pilocarpine for use on the oral mucosa, however, may be an effective alternative.
Read the clinical trial that evaluates the viability of mucoadhesive pilocarpine in
General Dentistry.